- Abeona Therapeutics (NASDAQ:ABEO) initiated with Buy rating and $22 (340% upside) price target by Jefferies.
- Alnylam (NASDAQ:ALNY) initiated with Buy rating with $102 (21% upside) price target by Jefferies.
- Atara Biotherapeutics (NASDAQ:ATRA) initiated with Buy rating and $30 (109% upside) price target by Jefferies.
- Dermira (NASDAQ:DERM) initiated with Overweight rating and $45 (48% upside) price target by Canto Fitzgerald.
- Intellia Therapeutics (NASDAQ:NTLA) initiated with Buy rating and $36 (140% upside) price target by Jefferies.
- Paratek Pharmaceuticals (NASDAQ:PRTK) initiated with Overweight rating and $50 (112% upside) price target by Canto Fitzgerald.
- Ignyta (NASDAQ:RXDX) initiated with Buy rating and $27 (170% upside) price target by Jefferies.
- Sangamo Therapeutics (NASDAQ:SGMO) initiated with Buy rating and $17 (109% upside) price target by Jefferies.
- Mednax (NYSE:MD) upgraded to Equal Weight with a $68 (18% upside) price target by Stephens.
- Now read: Alnylam Still Has A Lot Of Upside: Bhavneesh Sharma's Idea Of The Month
Original article